Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Rating Upgraded by StockNews.com

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Trading Down 3.2 %

Shares of AUPH opened at $8.07 on Thursday. The firm’s 50-day moving average price is $8.74 and its 200-day moving average price is $7.22. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -53.80 and a beta of 1.24. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals has a 1-year low of $4.71 and a 1-year high of $10.67.

Insider Buying and Selling

In related news, Director Jeffrey Allen Bailey sold 4,557 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the sale, the director now owns 13,356 shares of the company’s stock, valued at $112,591.08. The trade was a 25.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 4.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several hedge funds have recently bought and sold shares of AUPH. FMR LLC lifted its stake in shares of Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after buying an additional 3,919 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Aurinia Pharmaceuticals by 10.0% in the second quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the biotechnology company’s stock worth $301,000 after buying an additional 4,808 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in shares of Aurinia Pharmaceuticals by 13.2% in the third quarter. Handelsbanken Fonder AB now owns 60,700 shares of the biotechnology company’s stock worth $445,000 after buying an additional 7,100 shares in the last quarter. PFG Investments LLC lifted its stake in shares of Aurinia Pharmaceuticals by 37.9% in the second quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company’s stock worth $164,000 after buying an additional 7,900 shares in the last quarter. Finally, CWM LLC lifted its stake in shares of Aurinia Pharmaceuticals by 247.7% in the third quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock worth $84,000 after buying an additional 8,180 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.